ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours

Peer Review reports

Original Submission
27 Jul 2015	Submitted	Original manuscript
9 Aug 2015	Author responded	Author comments - Eva Segelov
Resubmission - Version 2
9 Aug 2015	Submitted	Manuscript version 2
30 Mar 2016	Reviewed	Reviewer Report - Devalingam Mahalingam
13 Apr 2016	Reviewed	Reviewer Report - Esther Black
15 Apr 2016	Reviewed	Reviewer Report - Eishi Baba
26 Apr 2016	Author responded	Author comments - Eva Segelov
Resubmission - Version 3
26 Apr 2016	Submitted	Manuscript version 3
3 May 2016	Reviewed	Reviewer Report - Esther Black
Resubmission - Version 4
	Submitted	Manuscript version 4
Publishing
26 May 2016	Editorially accepted
31 May 2016	Article published	10.1186/s12885-016-2389-8

Back to article page